Yujiro S. Hata
Founder, President, CEO & ChairmanMr. Yujiro S. Hata is Founder of IDEAYA Biosciences, Inc. and also serves as President, Chief Executive Officer & Chairman since June 2026. At the company, he also served as President, Chief Executive Officer & Director from June 2015 to June 2026. He serves as Venture Partner at The Column Group, LLC since November 2026, which he joined in 2026. He serves as Director at Hexagon Bio, Inc. since November 2024. He serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 19, 2021. He serves as Executive-in-Residence at 5AM Venture Management, LLC, which he joined in August 2015. Mr. Hata serves on the Board of Directors at Expansion Therapeutics and on the Board of visitors of the Moores Cancer Center, at the University of California, San Diego. Prior to his current roles, he served as an Independent Director at Xencor, Inc. from July 30, 2015 to September 2022. He was Chief Operating Officer at Flexus Biosciences, Inc. from 2014 to August 2015. He served as Vice President of Corporate Development and Strategy at Onyx Pharmaceuticals from 2010 to October 2013, where he also held leadership roles including Head of Strategy and Strategic Asset Management and Head of M&A Transactions and Licensing. At Enanta Pharmaceuticals, Inc., he served as Chief Business Officer and Senior Vice President from 2002 to 2010, Senior Vice President, Business Development from October 2005 to December 2008, and as Vice President, Business Development from October 2002 to September 2005. Earlier in his career, he served as Senior Director, Corporate Development of Oscient Pharmaceuticals and launched his industry career at ImClone Systems Incorporated where he helped to establish its first business development department. He also served as the Chief Executive Officer of eTechtransfer and as a Consultant at McKinsey & Company. He was a research intern at Columbia Medical School. Mr. Hata has been involved in forming major drug discovery alliances, including the Partnering of Erbitux, licensing of Phase III antibiotic Ramoplanin, EDP-420; the co-development Partnership between Genome Therapeutics and Amgen; and alliances with global pharmaceutical companies, such as Astra-Zeneca, Chiron, Merck KGaA and Shionogi. He completed his M.B.A. from the University of Pennsylvania - The Wharton School, as a Henry J Kaiser recipient, and his B.A. in Chemistry from Colorado College. He also did undergraduate studies in chemistry and biology at Oxford University.
Positions
- Company NameIDEAYA Biosciences, Inc.Stock CodeIDYAPositionFounder, President, CEO & ChairmanColleagues
- JBJoshua BleharskiChief Financial Officer
- ARAndres Ruiz BrisenoChief Accounting Officer
- DBDouglas B. SnyderChief Legal Officer
- MAMichael A. WhitePresident of Research & Development
- JLJeffrey L. SteinIndependent Director
- SWScott William MorrisonIndependent Director
- FPFrank P. McCormickChair of Scientific Advisory Board
- TJTerry J. RosenLead Independent Director
